Research ArticleBrief Communication
Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma
Jeeban P. Das, Hebert A. Vargas, Soleen Ghafoor, Alvin C. Goh and Gary A. Ulaner
Journal of Nuclear Medicine May 2021, 62 (5) 643-647; DOI: https://doi.org/10.2967/jnumed.120.251561
Jeeban P. Das
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
Hebert A. Vargas
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Soleen Ghafoor
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
2Department of Radiology, Weill Cornell Medical College, New York, New York
Alvin C. Goh
3Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; and
Gary A. Ulaner
1Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
4Molecular Imaging and Therapy, Hoag Family Cancer Institute, Newport Beach, California

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 62, Issue 5
May 10, 2021
Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma
Jeeban P. Das, Hebert A. Vargas, Soleen Ghafoor, Alvin C. Goh, Gary A. Ulaner
Journal of Nuclear Medicine May 2021, 62 (5) 643-647; DOI: 10.2967/jnumed.120.251561
Jump to section
Related Articles
Cited By...
- No citing articles found.